Advanced search
Publication Cover
mAbs Volume 11, 2019 - Issue 1
Submit an article Journal homepage
3,239
Views
10
CrossRef citations to date
0
Altmetric
Report

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models

Wei-Ying KuoGenomics Research Center, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0001-8006-3594View further author information
ORCID Icon,
Hung-Ju HsuGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Chun-Yi WuDepartment of Biomedical Imaging and Radiological Science, College of Medicine, China Medical University, Taichung, TaiwanORCID Iconhttps://orcid.org/0000-0002-8217-1692View further author information
ORCID Icon,
Hong-Sen ChenGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Yu-Chi ChouGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Yueh-Liang TsouGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Hung-Pin PengGenomics Research Center, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0002-9398-8120View further author information
ORCID Icon,
Jhih-Wei JianGenomics Research Center, Academia Sinica, Taipei, Taiwan;Institute of Biomedical Informatics, National Yang-Ming University, Taipei, Taiwan;Bioinformatics Program, Taiwan International Graduate Program, Institute of Information Science, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0001-9870-0678View further author information
ORCID Icon,
Chung-Ming YuGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Yi-Kai ChiuGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Ing-Chien ChenGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Chao-Ping TungGenomics Research Center, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0002-8699-3167View further author information
ORCID Icon,
Michael HsiaoGenomics Research Center, Academia Sinica, Taipei, TaiwanView further author information
,
Chia-Lung LinGenomics Research Center, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0002-0497-7164View further author information
ORCID Icon,
Yong Alison WangKoo Foundation Sun Yat-Sen Cancer Center, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0001-7361-348XView further author information
ORCID Icon,
Andrew H-J. WangInstitute of Biological Chemistry, Academia Sinica, Taipei, TaiwanORCID Iconhttps://orcid.org/0000-0002-0016-5337View further author information
ORCID Icon &
An-Suei YangGenomics Research Center, Academia Sinica, Taipei, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4699-873XView further author information
ORCID Icon show all
Pages 153-165 | Received 23 May 2018, Accepted 04 Oct 2018, Published online: 08 Nov 2018

References

  • Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40:770–780. doi:10.1016/j.ctrv.2014.02.008.
  • Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncology. 2008;19:1523–1529. doi:10.1093/annonc/mdn169.
  • Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M. HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol. 2017;14:669. doi:10.1038/nrclinonc.2017.96.
  • Metzger-Filho O, Winer EP. T-DM1 — an important agent in the history of breast cancer management. Nat Rev Clin Oncol. 2017;14:651. doi:10.1038/nrclinonc.2017.123.
  • Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–653. doi:10.1016/S1470-2045(17)30111-0.
  • Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–1522. doi:10.1016/S1470-2045(17)30604-6.
  • Chen I-C, Chiu Y-K, Yu C-M, Lee -C-C, Tung C-P, Tsou Y-L, Huang Y-J, Lin C-L, Chen H-S, Wang AH-J, et al. High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Sci Rep. 2017;7:14455. doi:10.1038/s41598-017-14823-w.
  • Chen HS, Hou SC, Jian JW, Goh KS, Shen ST, Lee YC, You -J-J, Peng H-P, Kuo W-C, Chen S-T, et al. Predominant structural configuration of natural antibody repertoires enables potent antibody responses against protein antigens. Sci Rep. 2015;5:12411. doi:10.1038/srep12411.
  • Hou SC, Chen HS, Lin HW, Chao WT, Chen YS, Fu CY, Yu C-M, Huang K-F, Wang AH-J, Yang A-S. High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries. Sci Rep. 2016;6:31878. doi:10.1038/srep31878.
  • Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–1465. doi:10.1182/blood-2003-01-0039.
  • Weldon JE, Pastan I. A guide to taming a toxin–recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278:4683–4700. doi:10.1111/j.1742-4658.2011.08182.x.
  • Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A. 1990;87:308–312.
  • Alewine C, Hassan R, Pastan I. Advances in anticancer immunotoxin therapy. The Oncologist. 2015;20:176–185. doi:10.1634/theoncologist.2014-0358.
  • Peng HP, Lee KH, Jian JW, Yang AS. Origins of specificity and affinity in antibody-protein interactions. Proc Natl Acad Sci U S A. 2014;111:E2656–65. doi:10.1073/pnas.1401131111.
  • Hsu HJ, Lee KH, Jian JW, Chang HJ, Yu CM, Lee YC, Chen I-C, Peng H-P, Wu CY, Huang Y-F, et al. Antibody variable domain interface and framework sequence requirements for stability and function by high-throughput experiments. Structure. 2014;22:22–34. doi:10.1016/j.str.2013.10.006.
  • Chang HJ, Jian JW, Hsu HJ, Lee YC, Chen HS, You JJ, Hou S-C, Shao C-Y, Chen Y-J, Chiu K-P, et al. Loop-sequence features and stability determinants in antibody variable domains by high-throughput experiments. Structure. 2014;22:9–21. doi:10.1016/j.str.2013.10.005.
  • Yu CM, Peng HP, Chen IC, Lee YC, Chen JB, Tsai KC, Chen C-T, Chang J-Y, Yang E-W, Hsu P-C, et al. Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. PLoS One. 2012;7:e33340. doi:10.1371/journal.pone.0033340.
  • Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature. 2003;421:756–760. doi:10.1038/nature01392.
  • Spooner RA, Smith DC, Easton AJ, Roberts LM, Lord JM. Retrograde transport pathways utilised by viruses and protein toxins. Virol J. 2006;3:26. doi:10.1186/1743-422X-3-99.
  • Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71:2250–2259. doi:10.1158/0008-5472.CAN-10-2277.
  • Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A. 1991;88:8616–8620.
  • Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP, Vallis K, Hendler A, Gariépy J. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med. 2000;41:429–438.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.